SIMPLY WALL St : Resultados PHARMAMAR del Tercer Trimestre de 2025 : Pérdida de 0,23 € Por Acción . Ingresos : 35,7 MILLONES de euros ( un 22 % Menos Que en el Tercer Trimestre de 2024 ) . Pérdida Neta : 4,10 MILLONES de euros ( un 205 % Menos Que las Ganancias del Tercer Trimestre de 2024 ) .
11 julio 2007
Patente Pharma Mar . Derivatives of ecteinascidin 736 are provided .
ANTITUMORAL ANALOGS .
Publication number: EP1806349 Publication date: 2007-07-11 Inventor: GALLEGO PILAR (ES); CUEVAS CARMEN (ES); MUNT SIMON (ES); MANZANARES IGNACIO (ES); MARTINEZ VALENTIN (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: C07D515/22; A61K31/438; A61K31/4985; A61K31/4995; A61P35/00; C07D515/00; A61K31/438; A61K31/4985; A61K31/4995; A61P35/00; - European: C07D515/22 Application number: EP20070001308 20020806 Priority number(s): EP20020753134 20020806; GB20010019243 20010807
Abstract of EP1806349
Derivatives of ecteinascidin 736 are provided
Publication number: EP1806349 Publication date: 2007-07-11 Inventor: GALLEGO PILAR (ES); CUEVAS CARMEN (ES); MUNT SIMON (ES); MANZANARES IGNACIO (ES); MARTINEZ VALENTIN (ES) Applicant: PHARMA MAR SA (ES) Classification: - international: C07D515/22; A61K31/438; A61K31/4985; A61K31/4995; A61P35/00; C07D515/00; A61K31/438; A61K31/4985; A61K31/4995; A61P35/00; - European: C07D515/22 Application number: EP20070001308 20020806 Priority number(s): EP20020753134 20020806; GB20010019243 20010807
Abstract of EP1806349
Derivatives of ecteinascidin 736 are provided
Suscribirse a:
Comentarios (Atom)